My understanding is that Teva will pay Biosante $5 Million upon FDA approval and a 10% royalty on sales. Interestingly The new merger between Jazz and Azur pharma has heightened the profile of Elestrin as well. Biosante gave up some royalties for up front cash for Elestrin but may receive milestone payments of up to $140 million based on sales. AIS whose technology was used in the making Elestrin has been receiveing royalties. It will be interesting to see if Elestrin sales grow to the point of reaching milestone payments.
Market Data 
Markets 
AI
